Alkem Labs hit with FDA 483 with three observations at Indian plant

By Dan Stanton

- Last updated on GMT

Image: iStock/Lemiuex
Image: iStock/Lemiuex

Related tags States and territories of india Food and drug administration Fda

The US FDA has issued a Form 483 with three observations to Alkem Laboratories after an inspection at its facility in Himachal Pradesh, India.

The Baddi facility was visited by a US Food and Drug Administration (FDA) inspection team between March 2nd​ and 10th​ resulting in a report containing three observations.

“The Company shall put together a detailed report with adequate corrective and preventative measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA,”​ Alkem Laboratories said in a filing submitted to the Bombay Stock Exchange​ Friday.

The firm was not available for immediate comment.

The inspection comes three months after​ the FDA issued a Form 483 at another Alkem site in Ankleshwar, Gujarat also citing three observations. A bio-analytical inspection at the firm’s facility in the Daman and Diu state was inspected in October​, with the FDA making no observations.

Alkem owns and operates 14 manufacturing facilities in India and two in the US.

Related news

Related product

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.